PAVM - Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors | Benzinga
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants
NEW YORK, Feb. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed"), today announced that it has contracted with the World Trade Center Health Program ("WTCHP") to provide the EsoGuard® Esophageal DNA test as a covered benefit to the more than 120,000 responders and survivors who participate in the program. The WTCHP provides medical monitoring and treatment to those directly affected by the 9/11 terrorist attacks, including members of the Fire Department of the City of New York (FDNY) and other emergency responders at the World Trade Center, recovery and cleanup workers and those who were in the New York City Disaster Area on September 11, 2001, or in the months that followed. EsoGuard is now reimbursable at $2,475.81 per test prescribed by clinicians at one of WTCHP's Clinical Centers of Excellence.